Glaukos (GKOS) director sells 15,000 shares after option exercise
Rhea-AI Filing Summary
Glaukos Corporation director Marc Stapley reported exercising stock options for 15,000 shares of common stock at an exercise price of $24.69 per share on January 22, 2026. On the same day, he sold an aggregate of 15,000 shares of common stock in multiple open-market transactions at weighted average prices ranging from about $126.07 to $129.78 per share under a pre-established Rule 10b5-1 trading plan adopted on June 4, 2025. After these transactions, Stapley held 37,449 shares of Glaukos common stock directly, which the footnote states includes 2,835 restricted stock units that have not yet vested or been delivered, as well as vested units for which delivery has been deferred.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 15,000 | $24.69 | $370K |
| Sale | Common Stock | 3,812 | $126.07 | $481K |
| Sale | Common Stock | 3,892 | $126.96 | $494K |
| Sale | Common Stock | 1,671 | $127.92 | $214K |
| Sale | Common Stock | 4,325 | $129.11 | $558K |
| Sale | Common Stock | 1,300 | $129.78 | $169K |
Footnotes (1)
- Includes 2,835 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 4, 2025. This transaction was executed in multiple trades at prices ranging from $125.59 to $126.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $126.756 to $127.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $127.58 to $128.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $128.59 to $129.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $129.62 to $130.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 4, 2025.
FAQ
What insider transaction did Glaukos (GKOS) director Marc Stapley report?
Marc Stapley reported exercising a stock option for 15,000 shares of Glaukos common stock at an exercise price of $24.69 per share on January 22, 2026, and selling a total of 15,000 shares of common stock in multiple open-market transactions the same day.
What stock option did Marc Stapley exercise in the Glaukos (GKOS) Form 4?
He exercised a stock option (right to buy) covering 15,000 shares of Glaukos common stock with an exercise price of $24.69 per share. The option had an original grant date of June 2, 2017 and an expiration date of June 2, 2026, and the Form 4 shows no remaining balance after exercise.
Were Marc Stapley’s Glaukos (GKOS) trades under a Rule 10b5-1 trading plan?
Yes. The footnotes state that both the reported sales of common stock and the option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Marc Stapley on June 4, 2025.
What does the Form 4 say about how the Glaukos (GKOS) trade prices were calculated?
The Form 4 explains that each sale transaction was executed in multiple trades within specified price ranges and that the price reported for each line reflects the weighted average price. The reporting person undertakes to provide full trade details to the SEC staff, the issuer, or any security holder upon request.